DrugDashboards

Doxorubicin Hydrochloride

Doxorubicin Hydrochloride · DOXORUBICIN HYDROCHLORIDE 2 mg/mL · Injectable, Liposomal · Intravenous · NorthStar RxLLC

NDC 72603-0200-01 · 1 VIAL, SINGLE-DOSE in 1 PACKAGE / 25 mL in 1 VIAL, SINGLE-DOSE · ANDA · View full market →

The short version

5 companies supply this market — a reasonable cushion if one runs into trouble. A Class I recall hit this product in the past year (Sun Pharmaceutical Industries Inc). One of its named manufacturing plants, Sun Pharmaceutical Industries Limited, failed FDA inspectionwithin the last two years — the agency’s most serious outcome.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed
$2,422.55
Reported to Texas DSHS · 2026 annual filing · Northstar Rx Llc

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 10 MG
$116.605
HCPCS Q2050 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2024)

$6,497
12 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA203263
TE code
AB
Approval date
Feb 4, 2013
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

  • Class I · OngoingMay 12, 2026
    SUN PHARMACEUTICAL INDUSTRIES INC — Presence of Particulate matter: Particulate matter identified as glass.

Manufacturers of Doxorubicin Hydrochloride (Injectable, Liposomal)

LabelerStrengthFirst seenLast seen
BluePoint LaboratoriesDOXORUBICIN HYDROCHLORIDE 2 mg/mLJul 15, 2026Sep 3, 2026
NorthStar RxLLCDOXORUBICIN HYDROCHLORIDE 2 mg/mLJul 15, 2026Sep 3, 2026
Sun Pharmaceutical Industries, Inc.DOXORUBICIN HYDROCHLORIDE 2 mg/mLJul 15, 2026Sep 3, 2026
Zydus Pharmaceuticals USA Inc.DOXORUBICIN HYDROCHLORIDE 2 mg/mLJul 15, 2026Sep 3, 2026
Zydus Lifesciences LimitedDOXORUBICIN HYDROCHLORIDE 2 mg/mLJul 15, 2026Aug 31, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Doxorubicin Hydrochloride — NDC 72603-0200-01," retrieved September 3, 2026, https://drugdashboards.com/drug/72603020001.

Free to cite with attribution — see how the data is put together.